Category: Medicine

Medicine

Lundbeck to buy brain drug developer Longboard for $2.6B

Danish drugmaker Lundbeck has agreed to spend $2.6 billion acquiring a young biotechnology company with an experimental brain medicine that

Medicine

FDA, facing pressure, to review position on Zepbound, Mounjaro shortage

The Food and Drug Administration has temporarily deflected a lawsuit alleging it violated federal law by removing Eli Lilly’s obesity

Medicine

Choosing the right hub partner: A blueprint for decision-makers

An effective launch sets the stage for a new drug’s long-term success. It shapes provider and patient perceptions, drives medication

Medicine

The number of AI medical devices has spiked in the past decade

The number of medical devices with artificial intelligence technology has risen sharply in the past decade. The Food and Drug

Medicine

Ex-Pfizer execs ‘threatened’ for supporting plans to shake up company, Starboard says

Two former Pfizer executives announced late Wednesday night that they won’t support efforts by activist investor Starboard Value to shake

Medicine

Upstream prices $255M IPO in bid to challenge Amgen, AstraZeneca asthma drug

Dive Brief: Upstream Bio announced Thursday it priced its initial public offering, raising $255 million to fund development of an antibody

Medicine

FDA clears Roche breast cancer drug; Turnstone lays off 60% of staff

Today, a brief rundown of news from Roche and Turnstone Biologics, as well as updates from Sanofi, Pfizer and Flagship

Medicine

Sanofi may have found a buyer for its consumer health business

For the past year, French pharmaceutical giant Sanofi has been searching for a buyer to take control of its consumer

Medicine

Upstream prices $255M IPO in bid to challenge Amgen, AstraZeneca asthma drug

Dive Brief: Upstream Bio announced Thursday it priced its initial public offering, raising $255 million to fund development of an antibody

Medicine

UnitedHealth, CVS push to remove FTC Chair Lina Khan from PBM case

Dive Brief: UnitedHealth Group and CVS Health want Federal Trade Commission Chair Lina Khan and two other commissioners to recuse

Medicine

Lilly partners with AI specialist Insitro to develop metabolic medicines

Dive Brief: Eli Lilly and Insitro said they have entered into three drug development deals that offer a “new paradigm”

Medicine

Purespring raises $105M to advance gene therapy for kidney disease

Biotechnology company Purespring Therapeutics has raised about $105 million to fund its development of gene therapies for diseases of the

Medicine

Sage continues downslide as Alzheimer’s study fails

Alzheimer’s disease remains one of the world’s most indomitable illnesses, and on Tuesday it defeated yet another potential treatment in

Medicine

Scholar Rock scores with ‘surprise’ success in SMA drug study

Dive Brief: An experimental, muscle-preserving therapy from Scholar Rock succeeded in a Phase 3 trial in spinal muscular atrophy, positioning

Medicine

GSK’s ViiV to expand supply of HIV drug in Africa

Dive Brief: GSK-backed ViiV Healthcare on Monday said it plans to triple the amount of its HIV prevention therapy it

Medicine

With $115M more, Triveni accelerates immune drug work

Dive Brief: Triveni Bio has raised $115 million in Series B funding, the company said Wednesday, adding to an upward

Medicine

Blue Shield of California sidesteps PBMs with new Humira biosimilar deal

Dive Brief: A major California health plan has struck a novel deal with a drug manufacturer for a cheaper version

Medicine

An Alzheimer’s drugmaker is accused of data manipulation. Should its trials be stopped?

Cassava Sciences has faced intense regulatory scrutiny over alleged clinical impropriety in studies of its experimental Alzheimer’s disease drug. Most

Medicine

Opdivo gets ‘perioperative’ approval; pharmas cut jobs in New Jersey, Ireland

Today, a brief rundown of news from Bristol Myers Squibb and Johnson & Johnson, as well as updates from Bayer,

Medicine

Sanofi’s rare disease drug finds yet another home

Over the past decade, the medicine Enjaymo has been passed around no less than five times by developers large and

Medicine

Editas trades Vertex fees for upfront cash in DRI deal

Dive Brief: Gene editing company Editas Medicines has sold off license fees and future payments it’s owed under an agreement

Medicine

FDA makes end of Zepbound, Mounjaro shortage official

Dive Brief: Shortages affecting the availability of Eli Lilly’s top-selling diabetes and weight-loss drugs have now been resolved, the Food

Medicine

Medicare tweaks rules for second round of drug price talks

The U.S. government is fine-tuning the rules for how it will negotiate drug prices within Medicare when the second round

Medicine

Gilead agrees to license new HIV drug in low-income countries

Dive Brief: Gilead on Wednesday said it signed royalty-free licensing agreements with six generic drugmakers to produce and sell its

Medicine

Lilly plans $4.5B ‘foundry’ for advanced drug manufacturing

Dive Brief: Eli Lilly on Wednesday announced plans to spend $4.5 billion on a new facility that will use advancements

Medicine

Startup led by former J&J executives raises $165M for cancer, immune disease drugs

Dive Brief: A two-year-old biotechnology startup led by former Johnson & Johnson executives has raised $165 million to develop “multifunctional”

Medicine

Merck claims late-stage study success for RSV antibody

Dive Brief: An experimental Merck & Co. drug designed to protect infants from illness caused by respiratory syncytial virus succeeded

Medicine

US government declines to clear Bluebird fertility support for Zynteglo patients

The U.S. government will not give Bluebird bio a green light to offer fertility support to federally insured people undergoing

Medicine

Ionis plots next steps for Angelman drug Biogen passed on

Ionis Pharmaceuticals plans to push one of its rare disease drugs into late-stage testing now that a smaller trial has

Medicine

NGM, now private, raises $122M for redrawn research plans

Dive Brief: NGM Biopharmaceuticals, which was taken private earlier this year, has raised $122 million from venture investors to advance

Medicine

Gilead’s CMO to depart next year

Dive Brief: Gilead chief medical officer Merdad Parsey will step down from his role and leave the biotechnology company early

Medicine

Caribou lays off staff; Roche walks away from Relay

Today, a brief rundown of news from Caribou Sciences and Relay Therapeutics as well as updates from Corden Pharma, Celldex

Medicine

Obesity pill from Roche shows promising weight loss in small study

Dive Brief: A closely watched obesity pill being developed by Roche helped people in a small Phase 1 trial lose

Medicine

Lilly alone in bidding for Morphic; Novartis won’t yet file MorphoSys drug

Today, a brief rundown of news from Morphic Holding as well as updates from Novartis, the Parker Institute and Agenus

Medicine

Global tech outage hits US hospitals

Cybersecurity firm CrowdStrike triggered a massive IT outage on Friday, disrupting businesses, including healthcare, after issuing what was supposed to be a

Medicine

Artiva prices $167M IPO, riding optimism for autoimmune cell therapy

Dive Brief: Artiva Biotherapeutics on Thursday raised $167 million in an initial public offering centered around the promise of donor-derived cell

Medicine

Boehringer cuts price of Humira biosimilar in bid to build use

Boehringer Ingelheim will sell an unbranded version of its Humira biosimilar at a 92% discount to the list price of

Medicine

In strengthening Spravato sales, a positive sign for psychedelic drugs

Dive Brief: Sales of Johnson & Johnson’s depression drug Spravato accelerated in the second quarter, putting the medicine on pace

Medicine

Medical device firms have cut more than 14,000 jobs in the past 18 months

Medical device companies have been steadily cutting jobs for the past 18 months, eliminating thousands of positions as firms look

Medicine

Vertex taps Orum to hunt for better ‘preconditioning’ drugs

Vertex Pharmaceuticals is exploring new ways to prepare patients for intensive therapies like its sickle cell treatment Casgevy, announcing Tuesday

Medicine

Cardurion raises another $260M to fuel heart drug pipeline

Dive Brief: Biotechnology startup Cardurion Pharmaceuticals on Tuesday raised a $260 million Series B round that will help it build

Medicine

Asceneuron raises another $100M for Alzheimer’s drug development

Asceneuron, a Switzerland-based biotechnology company, has raised another $100 million to support its work developing drugs that target a protein

Medicine

Revolution Medicines firms up Phase 3 trial plans with latest cancer drug data

Dive Brief: An experimental cancer drug developed by Revolution Medicines shrank pancreatic tumors in about one-quarter of participants who had

Medicine

Amylyx, with GLP-1 buy, doubles down on blood sugar drugs

Amylyx Pharmaceuticals achieved what all upstart drugmakers hope to accomplish. In less than 10 years, the Massachusetts-based biotechnology company identified

Medicine

As GLP-1 drugs boom, other healthcare companies are cashing in

The popularity of new GLP-1 drugs for weight loss is giving rise to a secondary market with large revenue potential,

Medicine

Flagship raises $3.6B for biotech investing

Dive Brief: Flagship Pioneering said Wednesday that it’s added another $3.6 billion to its capital base, bringing the total raised

Medicine

FDA’s lab-developed test rule could be first test of agency’s power post-Chevron

The recent U.S. Supreme Court decision to overturn the Chevron doctrine could open the door to more challenges of Food

Medicine

Bristol Myers’ leukemia blockbuster set to face generic rivals

Pharmaceutical companies face a looming patent cliff over the next several years, as generic rivals could erode sales of some

Medicine

Leqembi sales inch higher; Spark’s pivot leads to layoffs

Today, a brief rundown of news from Eisai, Spark Therapeutics and Ipsen as well as updates from Element Biosciences and

Medicine

Novo’s once-weekly insulin rejected by FDA

Dive Brief: The Food and Drug Administration rejected Novo Nordisk’s application to sell a once-weekly insulin treatment called icodec, sending

Medicine

Pfizer thinks it found its obesity pill

With tens of billions of dollars at stake, some of the world’s largest drug companies are racing to develop pills

Medicine

FTC to sue three largest PBMs over drug price practices: WSJ

Dive Brief: The Federal Trade Commission is preparing to sue the three largest pharmacy benefit managers in the U.S. —

Medicine

AbbVie names new R&D head; Arcutis eczema cream approved

Today, a brief rundown of news from AbbVie and Skyhawk Therapeutics, as well as updates from Arcutis Biotherapeutics and Zevra

Medicine

SciRhom pulls in $70M for a new type of immune disease drug

SciRhom, a German biotechnology startup focused on autoimmune diseases, has raised a $70 million Series A funding round that will

Medicine

FTC criticizes PBM power over prescription drug market

The Federal Trade Commission on Tuesday released a long-awaited report criticizing the pharmacy benefit manager industry for manipulating the drug

Medicine

HilleVax’s norovirus vaccine ineffective in large trial of infants

Dive Brief: Biotechnology company HilleVax on Monday said it will halt development of an experimental norovirus vaccine in infants after

Medicine

Lilly to buy Morphic in $3B bet on inflammation drug

Eli Lilly plans to spend $3.2 billion acquiring a Massachusetts-based biotechnology company and its experimental pill for inflammatory bowel disease.

Medicine

With revised IPO pitch, Artiva touts ‘natural killer’ cell therapy for autoimmune disease

Dive Brief: Two years after canceling an initial public offering, Artiva Biotherapeutics has filed a new proposal centered around plans

Medicine

UniQure, with sale of plant, outsources Hemgenix manufacturing

Dive Brief: UniQure will sell a gene therapy production plant in Lexington, Massachusetts, to contract manufacturer Genezen in a deal

Medicine

Cartesian data add to progress, questions for CAR-T in autoimmune disease

Dive Brief: Cartesian Therapeutics on Tuesday said an experimental cell therapy it’s developing succeeded in a mid-stage clinical trial of

Medicine

5 FDA decisions to watch in the third quarter

Two of last year’s largest biotechnology company acquisitions centered on a new type of treatment for schizophrenia. By the end

Medicine

Beacon raises $170M for eye gene therapy; J&J confirms Carvykti survival benefit

Today, a brief rundown of news from Beacon Therapeutics and Regeneron Pharmaceuticals, as well as updates from Vertex Pharmaceuticals, Johnson

Medicine

CureVac cuts jobs, licenses out vaccines to GSK

Dive Brief: CureVac, a specialist in messenger RNA-based therapies, disclosed Wednesday plans to lay off 30% of its workforce as

Medicine

Moderna gets US funding for bird flu vaccine development

The U.S. government has awarded $176 million to vaccine maker Moderna for development of an mRNA-based influenza shot. The funding

Medicine

Lilly drug for Alzheimer’s approved by FDA

The Food and Drug Administration on Tuesday approved a new Alzheimer’s disease drug from Eli Lilly, several weeks after a

Medicine

Eli Lilly inks another radiopharma deal, gaining option to buy startup

Dive Brief: Eli Lilly is expanding further into radiopharmaceuticals, inking a deal with Radionetics Oncology that gives it an option

Medicine

Eisai and Bristol Myers cancel cancer ADC deal

Dive Brief: Eisai and Bristol Myers Squibb will cancel a collaboration on a dual-acting drug being developed to treat lung

Medicine

These microscopic tunnels are a goldmine for new medicines

After months of searching, the drug hunters had tracked down the prized game they believed could help launch the next

Medicine

Alumis cuts IPO size, but nets $250M for immune drug work

Immune drug developer Alumis has raised $210 million in one of the biotechnology sector’s largest initial public offerings this year.

Medicine

Supreme Court overturns Chevron doctrine, limiting reach of federal agencies

Dive Brief: The U.S. Supreme Court overturned the Chevron doctrine on Friday in a decision that could dramatically limit federal

Medicine

PTC faces another Duchenne drug rejection; Coherus sells Humira biosimilar

Today, a brief rundown of news from PTC Therapeutics, Esperion Therapeutics and Coherus Biosciences, as well as updates from Sanofi,

Medicine

Rocket gene therapy rejected by FDA over manufacturing

Dive Brief: The Food and Drug Administration has rejected a gene therapy developed by Rocket Pharmaceuticals for a rare type

Medicine

Merck’s pneumococcal vaccine gets CDC panel backing

Dive Brief: Advisers to the Centers for Disease Control and Prevention on Thursday unanimously recommended Merck & Co.’s recently approved

Medicine

2seventy slims down with sale of hemophilia assets to Novo

Dive Brief: 2seventy Bio is shrinking further, announcing Thursday the sale of a hemophilia A research program, along with associated

Medicine

RSV vaccine makers’ shares fall as CDC adjusts shot guidance

Dive Brief: Shares of Moderna, Pfizer and GSK fell as advisers to the Centers for Disease Control and Prevention discussed

Medicine

Novo nixes trial of blood pressure drug it bought in deal worth $1.3B

Dive Brief: Novo Nordisk will end a Phase 3 clinical trial of a hypertension drug it bought for up to

Medicine

Women with a common hormonal disorder have few good treatment options. Could GLP-1 drugs help?

Ozempic and GLP-1 drugs like it became household names due to their potent weight loss benefits, and are now proving

Medicine

Wave, with new data, plots path forward for Huntington’s drug

Dive Brief: Wave Life Sciences on Tuesday said it will meet with regulators to discuss what kind of evidence would

Medicine

Novo to spend $4B on US plant, adding to obesity drug production push

Dive Brief: Novo Nordisk will spend $4.1 billion to build a new U.S. factory in North Carolina, the latest multibillion-dollar

Medicine

Novo fills in positive picture for preventive hemophilia drug

Dive Brief: Novo Nordisk on Sunday disclosed detailed clinical trial results for an experimental hemophilia treatment dubbed Mim8, showing once-weekly

Medicine

Obesity drugs from Altimmune, Hengrui show potential; Lilly details Zepbound sleep apnea data

Today, a brief rundown of news from Altimmune, Jiangsu Hengrui, Eli Lilly and others that you might have missed from over

Medicine

Amazon expands drug subscription program to Medicare members

Dive Brief: Amazon has expanded its generic drug savings program to Prime members on Medicare, throwing open the program’s doors

Medicine

Twice-yearly shots of Gilead HIV drug effective in large prevention study

Dive Brief: Twice-yearly shots of a Gilead Sciences HIV drug were so effective at preventing infections in a large late-stage

Medicine

Obesity drug from Zealand shows potential in early trial

An experimental weight loss shot developed by Denmark-based Zealand Pharma helped people with obesity lose as much as 9% of

Medicine

Jazz drug for tremor fails study; Radiopharma drug developer ITM swaps CEOs

Today, a brief rundown of news from Jazz Pharma, Vanda Pharmaceuticals, ITM, Ashibio and Novartis that you might have missed

Medicine

Duchenne approval exposes FDA rift over Sarepta gene therapy

Peter Marks is again at the center of a controversial Food and Drug Administration decision on a gene therapy for

Medicine

Sarepta Duchenne gene therapy wins broader use from FDA

The Food and Drug Administration has substantially loosened limits on the first gene therapy for Duchenne muscular dystrophy in a

Medicine

FDA lifts hold on PTC Huntington’s disease trial

Dive Brief: PTC Therapeutics said Thursday it can resume a Phase 2 trial of its Huntington’s disease drug in the

Medicine

Roche partners with RNA editing biotech Ascidian

Roche has partnered with Ascidian Therapeutics to develop so-called “RNA exon editing” drugs, the latest foray by the Swiss pharmaceutical

Medicine

Sanofi taps Belharra for immune drug research; AstraZeneca’s new cancer drug falls short

Today, a brief rundown of news from Belharra Therapeutics, AstraZeneca, Regenxbio and Tasyha Gene Therapies. Sanofi will work with biotechnology

Medicine

Intra-Cellular depression drug succeeds in second late-stage study

Dive Brief: Intra-Cellular Therapies plans to seek clearance to sell its medicine Caplyta for patients with depression after a second-late

Medicine

Merck wins FDA OK for vaccine rival to Pfizer’s pneumococcal shot

Dive Brief: The Food and Drug Administration on Monday approved a new vaccine from Merck & Co. that protects against

Medicine

Takeda drug for rare types of epilepsy misses goal in late-stage trial

Dive Brief: An experimental pill developed by Takeda to treat the rare epilepsies Dravet and Lennox-Gastaut syndromes missed the main

Medicine

AbbVie joins in latest gastrointestinal drug chase

AbbVie is securing its place in an emerging gastrointestinal disease drug field, paying China-based FutureGen Biopharmaceutical $150 million in immediate

Medicine

Radiopharma drugmaker Telix pulls US IPO plans

Dive Brief: Telix, an Australia-based developer of radiopharmaceutical drugs for cancer, has canceled plans to raise roughly $200 million via

Medicine

Moderna says next-gen COVID shot effective in study

Dive Brief: Moderna said its next-generation COVID-19 vaccine succeeded in a Phase 3 study, offering increased effectiveness for adults. The

Medicine

Supreme Court preserves access to abortion pill in unanimous ruling

The Supreme Court on Thursday unanimously ruled an anti-abortion group contesting the Food and Drug Administration’s approval of the abortion

Medicine

Pfizer gene therapy for Duchenne fails to meet goals of key trial

Pfizer’s experimental gene therapy for Duchenne muscular dystrophy didn’t improve the motor function of young boys enrolled in a late-stage

Medicine

Avidity drug for muscular dystrophy shows promise; Syntis takes new approach to weight loss

Today, a brief rundown of news from Avidity Biosciences and Nodthera, as well as updates from Syntis Bio, QurAlis and

Medicine

Donanemab approval would fuel growth of amyloid-blocking Alzheimer’s drugs, analysts say

Approval of Eli Lilly’s experimental Alzheimer’s disease drug donanemab would help drive sales of Eisai and Biogen’s rival medicine Leqembi,

Medicine

Ipsen drug for rare liver disease approved by FDA

Dive Brief: The Food and Drug Administration on Monday cleared a new treatment option for the rare liver disease primary

Medicine

Lilly Alzheimer’s drug gets unanimous backing of FDA panel

An experimental and closely watched medicine for Alzheimer’s disease is one step closer to approval, after receiving support from a

Medicine

Alumis readies IPO to fund rival drug to Bristol Myers’ Sotyktu

Listen to the article 4 min This audio is auto-generated. Please let us know if you have feedback. Dive Brief:

Medicine

Germany’s ITM raises $205M as radiopharma field booms

Dive Brief: Radiopharmaceutical drug developer ITM has raised 188 million euros, or about $205 million, to fund its development of

Medicine

Seres, indebted and in need of cash, agrees to sell microbiome pill to Nestle

Dive Brief: Seres Therapeutics plans to sell all the rights to its microbiome pill to Nestlé Health Science as it

Medicine

As biotech recovers, venture firms’ preferences appear to shift

After a turbulent few years, 2024 has given the biotechnology industry some signs of a return to normalcy. For one,

Medicine

In review of Lilly Alzheimer’s drug, FDA staff focus on safety, patient selection

Dive Brief: Expert advisers to the Food and Drug Administration will need to weigh whether Eli Lilly’s experimental Alzheimer’s disease

Medicine

After ‘sobering’ FDA panel, psychedelics supporters wonder what’s next

Long dismissed by top scientists and drug regulators, the use of psychedelics to treat mental health conditions has finally gained

Medicine

Geron wins long-sought drug approval; Califf talks China, GLP-1s at BIO

Today, several brief updates from BioPharma Dive Reporter Gwendolyn Wu, who spent this week attending BIO’s annual meeting in San

Medicine

GSK acquires oligonucleotide drug startup Elsie

Listen to the article 2 min This audio is auto-generated. Please let us know if you have feedback. British drugmaker

Medicine

FDA advisers back updating COVID shots to target JN.1 virus family

A group of advisers to the Food and Drug Administration on Wednesday unanimously recommended that COVID-19 vaccines be updated to

Medicine

Lilly details MASH data for tirzepatide; Cytokinetics comments on past sale talks

Today, a brief rundown of news from Eli Lilly, Cytokinetics and AbbVie, as well as updates from Gilead and the

Medicine

Lilly CFO leaves to join Alphabet

Dive Brief: Anat Ashkenazi will leave Eli Lilly’s executive suite at the end of July to become CFO and senior

Medicine

FDA panel votes against MDMA therapy for PTSD, citing muddy data and safety concerns

Medical experts who advise the Food and Drug Administration are not convinced MDMA is ready for general use to help

Medicine

Structure pill leads to competitive weight loss in obesity study

Dive Brief: An experimental GLP-1 pill helped people with obesity lose significantly more weight than a placebo over three months,

Medicine

ASCO24: Tagrisso in the spotlight, Caribou’s adjustment and Lilly’s KRAS competitor

BioPharma Dive is testing out a new format rounding up smaller updates from around the industry. Have thoughts on what

Medicine

A true liquid biopsy hub – Menarini Silicon Biosystem

Liquid biopsy has emerged as a revolutionary tool for clinical trials, offering cellular and cell-free methods that provide valuable insights

Medicine

AstraZeneca immunotherapy extends survival by two years in rarer type of lung cancer

AstraZeneca’s immunotherapy Imfinzi helped people in the early stages of a type of lung cancer live 23 months longer than

Medicine

With new Enhertu data, an ADC could overtake chemo in breast cancer

Two years ago, a drug called Enhertu changed the way doctors thought about treating an aggressive form of breast cancer,

Medicine

Gilead’s Trodelvy misses goal in bladder cancer study

An accelerated approval for Gilead Sciences’ cancer drug Trodelvy could be in question after the company disclosed Thursday afternoon that a

Medicine

FDA delays decision on Dupixent in COPD; Summit makes a bold claim

BioPharma Dive is testing out a new format rounding up smaller updates from around the industry. Have thoughts on what

Medicine

FDA staff outline shortcomings of Lykos data for MDMA therapy

Food and Drug Administration scientists have reservations about a potential new treatment for post-traumatic stress disorder that’s currently up for

Medicine

Moderna wins FDA approval for RSV vaccine

The Food and Drug Administration on Friday approved a third vaccine for respiratory syncytial virus, clearing a shot from biotechnology

Medicine

Immunovant changes up plans for closely watched autoimmune drugs

Dive Brief: Immunovant told investors Wednesday that it’s shifting resources to focus on a less advanced experimental autoimmune disease treatment

Medicine

Otsuka defies digital health downturn with new company

Otsuka America, a subsidiary of the Japanese drug and device maker, this month launched a new company focused on digital

Medicine

A biotech working on a new approach to IVF raises $33M in fresh funding

Dive Brief: Gameto, a biotechnology company developing new treatments for fertility, has raised $33 million in venture capital funding to

Medicine

Agios cashes in on cancer drug again with $905M Royalty Pharma deal

Dive Brief: Agios Pharmaceuticals has agreed to sell to Royalty Pharma rights to royalties on a brain cancer drug it

Medicine

Insmed shares double as lung drug data convince Wall Street

New Jersey-based drugmaker Insmed gained more than $3 billion in market value Tuesday after reporting clinical trial results for an

Medicine

J&J gains another bispecific antibody with $1.25B skin drug buy

Dive Brief: Johnson & Johnson is adding to its portfolio of dual-targeting antibody drugs, announcing on Monday a deal to

Medicine

Regeneron faces new biosimilar threats; an AI biotech lays off staff

BioPharma Dive is testing out a new format rounding up smaller updates from around the industry. Have thoughts on what

Medicine

Cytokinetics secures up to $575M in royalty deal, frustrating investors

Dive Brief: Shares in Cytokinetics sank by about one-fifth Thursday on news of a funding deal the biotechnology company struck

Medicine

Merck KGaA to buy gene therapy tools maker for $600M

Dive Brief: German drugmaker Merck KGaA agreed to buy Mirus Bio for $600 million to build expertise in a critical

Medicine

Orna, a circular RNA specialist, acquires a buzzy startup

Orna Therapeutics, a young biotechnology company focused on a flashy area of genetic research, is expanding through the acquisition of

Medicine

Lilly to pour $5B more into expanding Zepbound, Mounjaro production

Eli Lilly plans to spend another $5.3 billion building production capacity for its popular obesity and diabetes drugs, responding to

Medicine

With Duchenne decision ahead, FDA’s Marks pushes for speedy gene therapy approvals

A top Food and Drug Administration official on Friday again advocated for the speedy approval of gene therapies for rare

Medicine

ASCO24: An early look at cancer drug study results

BioPharma Dive is testing out a new format rounding up smaller updates from around the industry. Have thoughts on what

Medicine

Certain menopausal hormone therapy could raise ovarian cancer risk, study finds

An older form of hormone therapy taken to ease the symptoms of menopause could increase the risk of ovarian cancer,

Medicine

Biogen, looking to diversify, acquires immune drugmaker HI-Bio for $1.15B

Dive Brief: Biogen is scooping up a closely held immunology startup to bring more diversity to a pipeline best known

Medicine

Pfizer expands cost cuts with new $1.5B target

Pfizer, already in the midst of an aggressive effort to trim spending, on Wednesday disclosed new plans to cut at

Medicine

SixPeaks, a new obesity biotech, starts up with an option to sell to AstraZeneca

A new obesity drug developer from investment firm Versant Ventures is starting up with a deal to possibly sell itself

Medicine

AstraZeneca’s $80B sales plan leans on cancer drug expansion

Dive Brief: AstraZeneca’s plan to reach $80 billion in sales by 2030 relies heavily on a slate of roughly one

Medicine

AltruBio lands up to $225M after shift to immune drug research

Dive Brief: Biotechnology startup AltruBio on Tuesday raised a Series B round that could hand it up to $225 million, cashing

Medicine

Forbion-backed biotech Progentos debuts with $65M for MS drug

Forbion, a well-known backer of life sciences startups, is leading an investment round for a newly launched biotechnology company focused

Medicine

Therapies designed to dismantle cancer’s escape mechanisms show promise for patients

Dr. Zocca brings more than 20 years of experience in the biotechnology field and has founded and co-founded several biotech

Medicine

Biogen, Ionis shelve ALS drug following study failure

Biogen and Ionis Pharmaceuticals are stopping development of an experimental drug for ALS following new clinical trial results that didn’t

Medicine

Roche keeps pace in obesity drug field with early study data

Dive Brief: An experimental Roche drug helped people with obesity lose an average of nearly 19% of their body weight

Medicine

Lilly’s once-weekly insulin matches daily shots in late-stage tests

A once-weekly form of insulin being developed by Eli Lilly proved just as effective at controlling blood sugar in adults

Medicine

Investors put $400M into biotech licensing obesity drugs from China

Four life science investors are pouring $400 million into a new biotechnology startup that’s licensed a portfolio of weight loss

Medicine

FDA approves Amgen drug for tough-to-treat form of lung cancer

Dive Brief: The Food and Drug Administration on Thursday granted accelerated approval to a new dual-acting drug from Amgen to

Medicine

Erasca restructures; Novartis moves to complete MorphoSys deal

BioPharma Dive is testing out a new format rounding up smaller updates from around the industry. Have thoughts on what

Medicine

Detailed trial data show Bayer drug alleviates menopause symptoms

New data from two late-stage studies of an experimental Bayer drug show it reduced the frequency and severity of common

Medicine

Bolt Biotherapeutics to lay off staff, abandon lead ADC candidate

San Francisco-based Bolt Biotherapeutics on Tuesday said it is ending development of its lead cancer drug, laying off half its

Medicine

Eisai sets new revenue target for Alzheimer’s drug Leqembi

One of the developers behind the Alzheimer’s disease drug Leqembi has set new revenue expectations that some analysts see as

Medicine

FogPharma, Artbio join forces to design a different radiopharma drug

FogPharma and Artbio, two buzzy biotechnology companies, are betting they can combine their respective technologies to design a new type

Medicine

Bayer details layoffs as company shake-up continues

German pharmaceutical company Bayer eliminated 1,500 roles during the first three months of the year as part of a company

Medicine

Sanofi gambles $80M on Fulcrum’s muscular dystrophy drug

Listen to the article 3 min This audio is auto-generated. Please let us know if you have feedback. Dive Brief:

Medicine

Takeda nabs option to license Alzheimer’s immunotherapies from AC Immune

Takeda Pharmaceutical is betting potentially billions of dollars on drugs designed to slow Alzheimer’s disease by harnessing the immune system.

Medicine

NewVale, an unorthodox venture firm, sets out to support biotech’s ‘infrastructure’

Dive Brief: An unorthodox life sciences venture firm closed its inaugural fund on Monday, a $167 million bankroll that will

Medicine

AstraZeneca withdraws COVID-19 vaccine, citing declining demand

Dive Brief: AstraZeneca will no longer manufacture or supply its COVID-19 vaccine Vaxzevria, announcing Tuesday it is voluntarily withdrawing the shot

Medicine

Novavax gets a lifeline with Sanofi vaccine pact

Dive Brief: Sanofi will pay vaccine maker Novavax $500 million and take a small equity stake in the Maryland-based company

Medicine

Maze lands new partner for Pompe drug, after Sanofi pact came apart

Dive Brief: Biotechnology startup Maze Therapeutics has licensed a Pompe disease drug to Shionogi, five months after a challenge from

Medicine

FDA delays decision on Moderna RSV vaccine

Moderna on Friday said the Food and Drug Administration has postponed an approval decision on its experimental vaccine for respiratory

Medicine

iTeos shares jump on TIGIT update; Acelyrin swaps CEOs

BioPharma Dive is testing out a new format rounding up smaller updates from around the industry. Have thoughts on what

Medicine

Royalty Pharma pays startup $525M for stake in Sanofi MS drug

Dive Brief: Royalty Pharma will pay biotechnology startup ImmuNext $525 million for the right to earn royalties and milestone payments

Medicine

Takeda targets ‘efficiency’ in restructuring, pipeline cuts

Dive Brief: Takeda plans to simplify how its workforce is organized, cut spending and slim down its drug pipeline in

Medicine

Novo taps another Flagship startup in search for next obesity drugs

Novo Nordisk is again turning to a Flagship Pioneering startup to find new weight loss drugs, announcing on Thursday a

Medicine

Drug patents protect pharma profits. Track when they’ll expire here.

Patents reward drugmakers for their inventions and, effectively, the large sums of money they invest in research and development. The

Medicine

Verve moves forward with backup base editing therapy

Dive Brief: Verve Therapeutics has treated the first participant in a recently begun clinical trial of the company’s backup gene

Medicine

Patient dies in Pfizer study of Duchenne gene therapy

A young boy enrolled in a clinical trial testing an experimental Pfizer gene therapy for Duchenne muscular dystrophy has died,

Medicine

Prologue, Flagship’s newest startup, looks to mine viruses for new drugs

Dive Brief: Flagship Pioneering on Tuesday launched Prologue Medicines, a new biotechnology startup aiming to make drugs by closely studying

Medicine

Gossamer sells rights to drug it hopes can rival a new Merck therapy

Gossamer Bio has sold rights to an experimental drug that could rival a new medicine from Merck & Co., in

Medicine

Free pathway analysis: How much do you really save?

When it comes to data-driven science, your results are only as good as your data and your software. Whether free

Medicine

BridgeBio spinout launches with $200M for KRAS cancer drugs

Dive Brief: A group of well-known biotechnology investors is putting $200 million into a newly launched spinout of BridgeBio Pharma

Medicine

Moderna ends gene editing alliance with Metagenomi

Dive Brief: The gene editing company Metagenomi, which went public earlier this year, said a development partnership struck with Moderna

Medicine

CG follows big IPO with new results for bladder cancer drug

Dive Brief: An experimental drug from CG Oncology has driven bladder cancers into remission in about three-quarters of people who

Medicine

Why selling to Novartis made sense for Mariana

Mariana Oncology arrived at the J.P. Morgan Healthcare Conference this past January with momentum. The radiopharmaceutical drug developer had secured

Medicine

Amgen shares soar as executives outline obesity drug push

Dive Brief: Amgen shares soared by double digits Friday following its announcement an obesity drug it’s developing has shown enough

Medicine

Novartis to buy Mariana Oncology in radiopharmaceutical expansion

Dive Brief: Novartis is expanding its pipeline of radiopharmaceutical drugs, announcing Thursday it has agreed to pay $1 billion to

Medicine

Novo sees Wegovy sales dip on lower price, tight supply

Dive Brief: Sales of Novo Nordisk’s obesity drug Wegovy slowed over the first three months of 2024, compared to the

Medicine

Delphia starts up with $67M to make a new type of cancer drug

Cancer research is always evolving, as scientists search for ways to combat the tricks tumors use to evade drug therapies.

Medicine

GSK raises forecasts on strong vaccine, HIV drug sales

Dive Brief: GSK on Wednesday raised its financial forecasts for the year following strong quarterly sales of its vaccines and

Medicine

FDA defends lab test rule, as critics fear industry upheaval

Federal officials said a new rule expanding regulatory oversight of laboratory-developed tests will protect patients from inaccurate results while maintaining

Medicine

Lilly counts on manufacturing scale-up to unstick obesity drug supply

Eli Lilly expects that, by the second half of this year, it will be able to manufacture at least 50%

Medicine

Chasing Novo and Lilly: The obesity drugs that could challenge Wegovy and Zepbound

One study can start a pharmaceutical revolution. Four years ago, a large clinical trial run by Novo Nordisk showed a

Medicine

FDA finalizes lab developed test rule over industry opposition

Dive Brief: The Food and Drug Administration on Monday released a final rule strengthening its authority over laboratory developed tests,

Medicine

Repertoire pivot pays dividends with Bristol Myers deal

Dive Brief: Repertoire Immune Medicines, a biotechnology startup formed by Flagship Pioneering, announced Monday a deal with Bristol Myers Squibb

Medicine

Biogen sees ‘encouraging’ trends for postpartum depression drug

Dive Brief: Biogen has seen “encouraging early trends” in the launch of its postpartum depression pill Zurzuvae, revealing in first

Medicine

Moderna turns to AI to change how its employees work

Moderna is betting big on bespoke artificial intelligence assistants. The biotechnology company on Wednesday said it has expanded a partnership

Medicine

Bristol Myers to cut 6% of workforce, trim drug pipeline

Bristol Myers Squibb will cut 6% of its workforce in a restructuring meant to save $1.5 billion in costs by

Medicine

Pfizer hemophilia gene therapy arrives in US to uncertain future

Dive Brief: The Food and Drug Administration on Friday approved a new gene therapy for hemophilia, clearing Pfizer’s Beqvez for

Medicine

AbbVie tries to reassure investors on Humira biosimilar threat

Dive Brief: U.S. Humira sales fell 40% year over year during the first three months of 2024, to about $1.8

Medicine

BioMarin drops drug programs in pipeline cull

Dive Brief: BioMarin on Wednesday said it’s wrapped up a pipeline review and will stop investing in four experimental therapies

Medicine

AstraZeneca’s earnings surprise investors as cancer drugs fuel growth

AstraZeneca’s revenue and profits grew at a rapid clip over the first three months of the year, beating Wall Street

Medicine

Regeneron expands in gene editing with Mammoth deal

Dive Brief: Regeneron Pharmaceuticals is upping its investment in genetic medicine, announcing Thursday a $100 million deal with CRISPR drug

Medicine

Biogen: Don’t expect any big acquisitions this year

Investors who had hoped Biogen would do another flashy deal this year may not want to hold their breath, as

Medicine

Endeavor pulls in $132M to back cancer, lung disease drugs

Endeavor BioMedicines has raised $132.5 million in a Series C round designed to advance its two experimental medicines deeper into

Medicine

Former Bristol Myers CEO tapped as Novartis’ next board chair

Giovanni Caforio, the former CEO of Bristol Myers Squibb, is set to become the next board chairman of Novartis, which

Medicine

Ipsen, Skyhawk to develop RNA-targeting pills for rare brain diseases

Dive Brief: French pharmaceutical company Ipsen will work with privately held biotechnology company Skyhawk Therapeutics to make small molecule drugs

Medicine

Lilly to buy injectable drug plant in manufacturing ramp-up

Dive Brief: Eli Lilly on Monday said it will acquire a drug plant from Nexus Pharmaceuticals to expand its manufacturing

Medicine

How can pharma speed time to treatment? Digital tools can help

For patients diagnosed with rare diseases or chronic illnesses, treatment delays can seriously impact health outcomes. A meta-analysis of cancer